SEBI’s Confidential DRHP Route: A Practical Guide for IPO-Bound Companies

Confidential Pre-Filing DRHP Route: A Merchant Banker’s Post-Early-Adopter Read

A Category I merchant banker’s 2026 view on SEBI’s confidential pre-filing DRHP framework — how it actually works in practice, which issuers benefit, and where the early-adopter cases have exposed real trade-offs.

SEBI introduced the confidential pre-filing DRHP framework in November 2022 by amending the ICDR Regulations. The mechanism allowed Indian issuers, for the first time, to submit a Pre-Filed DRHP (PFD) with SEBI on a confidential basis before making any public disclosure. The intent was to align Indian practice with the US SEC confidential submission route used effectively by JOBS Act–era issuers, and to give Indian companies more flexibility on market timing and competitive protection during the pre-IPO window.

Three years in, the route has been used by a modest but meaningful number of issuers — Tata Play, PhysicsWallah, and a handful of others through 2023–25. In 2026, we are now at the point where the trade-offs are clear enough for a Category I merchant banker to give boards a considered recommendation on when this route is worth the additional complexity. Here is what the mandate experience actually looks like.

The two-stage architecture

The confidential route is not a shortcut to listing. It is a two-stage disclosure regime:

1. Stage 1 — Pre-Filed DRHP (PFD): The issuer files a confidential DRHP with SEBI. Only SEBI, the stock exchanges, and the merchant banker have access. Public disclosure is not required at this stage. SEBI review proceeds normally, typically three to four rounds of queries and responses over four to six months.
2. Stage 2 — Updated DRHP-I (UDRHP-I): Within eighteen months of SEBI’s in-principle observations on the PFD, the issuer files a publicly available Updated DRHP-I. This is the first public disclosure of the offering. It incorporates all SEBI observations already addressed during the confidential stage.

Following the UDRHP-I, the standard timeline resumes — 21-day public comment window, RHP filing with price band, book-building, allocation, and listing.

Why boards actually choose this route

• Market timing flexibility — the eighteen-month window between PFD in-principle observations and UDRHP-I filing lets the issuer wait for favourable market conditions without repeatedly refiling.
• Competitive protection — financials, business strategy, customer concentration, and unit economics do not become public during the SEBI review phase. Competitors cannot use the disclosures to pre-empt the offering.
• Testing SEBI response on novel structures — first-of-kind businesses (D2C, deep-tech, subscription models) can resolve SEBI comfort on new disclosure formats confidentially before public exposure.
• Reduced litigation risk on preliminary disclosures — when the DRHP goes public with SEBI observations already addressed, the exposure to public interest litigation on preliminary drafting is materially lower.

Where this route stops helping

• Not available for SME IPOs — the framework applies only to mainboard offerings, so smaller issuers cannot use it.
• Longer overall timeline — from PFD to listing is typically nine to eighteen months, versus four to six months for a traditional filing. Issuers with urgent capital needs face a mismatch.
• Higher advisory cost — two rounds of intensive disclosure preparation (PFD and UDRHP-I) mean higher legal, audit, and merchant banker fees. Add ten to twenty percent over a traditional filing.
• Two public filings pre-listing — UDRHP-I is public, then RHP is public. Boards sometimes overestimate the confidentiality benefit if they forget UDRHP-I is a full public document.

The merchant banker’s workflow — what is different

The BRLM role changes in three specific ways under this route:

• Coordination of the PFD is more iterative — SEBI queries can be more exploratory since the issuer is not under public timeline pressure.
• Anchor investor engagement is delayed by design — early conversations with anchors happen against a confidential document, requiring careful NDA architecture.
• The transition from UDRHP-I to RHP compresses the pricing and book-building window, so pre-listing marketing must be intensified.

Post-early-adopter learnings in 2026

From the mandate experience of the first three cohorts of confidential filers, four patterns are clear:

• SEBI query intensity is comparable to public filings — the review is not lighter because it is confidential. Issuers expecting a smoother ride are surprised.
• The eighteen-month window is real and often used — several early adopters delayed UDRHP-I by twelve months or more when market conditions changed.
• Competitor protection has held up — no confirmed cases of leaks from PFD reviews through 2025.
• The route works best for issuers with stable business models but market-timing sensitivity. It works less well for high-growth companies whose numbers move materially between PFD and UDRHP-I.

When I recommend this route to a board

• The issuer has genuine market-timing flexibility (no urgent capital need).
• The business model or financial architecture is novel enough that competitive intelligence protection is valuable.
• The board is comfortable absorbing higher advisory cost for procedural optionality.
• The issuer expects to grow substantially between PFD and UDRHP-I and wants to update the disclosure with better numbers.

When I recommend the traditional route instead

• SME issuers (they are not eligible anyway).
• Straightforward businesses with predictable disclosures.
• Issuers who need capital within six months.
• Cost-sensitive issuers who cannot absorb the additional 10–20% advisory spend.

Closing action list for boards considering the confidential route

• Have the merchant banker map both timelines side by side before committing.
• Budget the incremental advisory cost realistically.
• Design anchor investor NDA framework in month one, not later.
• Treat UDRHP-I as a full public document — do not underestimate the disclosure burden at that stage.
• Plan for market-timing optionality actively — the eighteen-month window is a real asset only if the board is prepared to use it.

The confidential pre-filing DRHP route is not the right answer for every issuer, but for the right profile it materially improves the pre-IPO experience. Three years of practice have made the trade-offs visible enough that boards can now make an informed choice rather than an experimental one.